Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC). -
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care. -
On the Radar for RCC in 2021: McGregor Discusses Combination Strategies, HIF-2α Inhibition, and Other Key Topics
Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021. -
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
UROLOGIC CANCERS NEWS
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Model Proposed to Guide Use of Adjuvant Radiation Therapy for MIBC
Imfinzi Indication for Urothelial Carcinoma Withdrawn
AstraZeneca Voluntarily Withdraws Imfinzi Indication in Locally Advanced or Metastatic Bladder Cancer
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
